Added by Peter Hofland, PhD on April 29, 2010 at 11:00am — No Comments
Cancer patients who have completed treatment would be better served if oncology treatment centers were equipped to offer them comprehensive, pro-active follow-up care, according to experts who presented at the survivorship forum 'Developing a Cancer Survivorship Program' being held in Atlanta (Wednesday April 28, 2010).
"Earlier detection and better treatment methods mean that two of every three adult cancer survivors are living five years after…Continue
Added by Peter Hofland, PhD on April 29, 2010 at 5:00am — No Comments
The use of electronic brachytherapy systems to deliver intraoperative radiation therapy (IORT) is growing as clinical experience demonstrates the isotope-free cancer treatment platform is a patient and physician friendly alternative. This is one of the conclusions presented to breast cancer surgeons during the 11th Annual Meeting of the American Society of Breast Surgeons in las Vegas, NV, April 28-May 2, 2010.
The conclusion is based on the results from…Continue
Added by Peter Hofland, PhD on April 28, 2010 at 5:00pm — No Comments
The North Central Cancer Treatment Group (NCCTG), a national clinical research group sponsored by the National Cancer Institute, plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast (mTNBC) cancer. These cancers…Continue
Added by Peter Hofland, PhD on April 27, 2010 at 11:00pm — No Comments
Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and LUPUS Ventures BV. Immunovo combines the most desirable features of synthetic immunogen development with the recent insights into mechanisms driving tumor growth and metastasis, to create highly specific and powerful in vivo therapeutic immune responses.…Continue
Added by Peter Hofland, PhD on April 27, 2010 at 11:00am — No Comments
The European Medicines Agency (EMEA) Pediatric Committee (PDCO) today released its findings requested that Cell Therapeutics, Inc submit an updated Pediatric Investigation Plan (PIP) for pixantrone following discussions about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer.
Following the request Cell Therapeutics, cexpects to…Continue
Added by Peter Hofland, PhD on April 21, 2010 at 7:00pm — No Comments
Added by Peter Hofland, PhD on April 19, 2010 at 1:00pm — No Comments